Discontinued — last reported Q2 '23
Copart Acquisitions decreased by 100.1% to -$5.00K in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 88.6%, from -$44.00K to -$5.00K. Over 3 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -37.5% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.25M | $1.25M | $26.65M | $26.65M | $26.65M | $26.65M | $0.00 | $0.00 | $0.00 | $0.00 | $1.00M | -$1.00K | $0.00 | $1.26M | -$44.00K | $0.00 | $10.00K | $4.70M | -$5.00K |
| QoQ Change | — | +0.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | -100.1% | +100.0% | — | -103.5% | +100.0% | — | >999% | -100.1% |
| YoY Change | — | — | — | — | >999% | >999% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | +25.6% | <-999% | — | — | +273.8% | +88.6% |